AB Science S.A. (ABscience)

Oncology Corporate Profile

HQ Location

51 JFK Parkway, First Floor West
Short Hills, NJ 7078

Company Description

AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicine in the United States and Europe. It focuses on therapies for the treatment of cancer, inflammatory diseases, and nervous system diseases. The company_†_s lead compound includes Masitinib, a tyrosine kinase inhibitor that targets mast cells and selected kinases, including c-Kit, PDGR, and Lyn. Masitinib is also in three ongoing Phase III trials for the treatment of various indications in humans. The company was founded in 2001 and is headquartered in Paris, France.

Website: http://www.ab-science.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
masitinib / AB1010multiple tyrosine kinase inhibitorGastrointestinal Stromal Tumors (GIST)III
masitinib / AB1010multiple tyrosine kinase inhibitorMelanomaIII
masitinib / AB1010multiple tyrosine kinase inhibitorMultiple MyelomaIII
masitinib / AB1010multiple tyrosine kinase inhibitorPancreatic cancerIII
masitinib / AB1010multiple tyrosine kinase inhibitorT-cell lymphomaIII
masitinib / AB1010multiple tyrosine kinase inhibitorBreast cancerII
masitinib / AB1010multiple tyrosine kinase inhibitorColorectal cancerII
masitinib / AB1010multiple tyrosine kinase inhibitorGastric cancerII
masitinib / AB1010multiple tyrosine kinase inhibitorHead & Neck cancerII
masitinib / AB1010multiple tyrosine kinase inhibitorHepatocellular carcinoma (HCC)II
masitinib / AB1010multiple tyrosine kinase inhibitorOvarian cancerII
masitinib / AB1010multiple tyrosine kinase inhibitorProstate cancerII
masitinib / AB1010multiple tyrosine kinase inhibitorTriple negative Breast cancer II

View additional information on product candidates here »

Source


http://www.ab-science.com/

Recent News Headlines

There are no news items to display